Levemir Insulin Is Being Withdrawn: What Families Need to Know Before December
Share
One minute you're collecting a familiar insulin prescription. The next, you're told the insulin you've used for years is being withdrawn. Not exactly what anyone wants to hear when Type 1 diabetes already brings enough daily decisions.
That is the situation facing people who use Levemir (insulin detemir). As November begins, an important deadline is approaching for healthcare teams across the UK. People in Ireland are affected too. Here's what you need to know without the medical jargon.
What's happening to Levemir?
Levemir is a long-acting, or basal, insulin. It provides background insulin between meals and overnight. Some people inject it once a day, while others use it twice daily. People using an insulin pump may also keep it as a backup for pump failure.
Its manufacturer is discontinuing Levemir worldwide. Both the FlexPen pre-filled pens and Penfill cartridges are affected.
This is not a new announcement from the past few days. However, a UK National Patient Safety Alert issued on 1 October 2026 reinforced the need for a planned change. UK supplies are expected to run out by the end of December 2026, potentially earlier in some areas.
The alert instructs UK clinicians to arrange switches as soon as possible and no later than 30 November 2026. That is a deadline for prescribers, not permission for anyone to change their own insulin.
What should you do if you use Levemir?
If Levemir is on your prescription and you haven't been given a switching plan, contact your diabetes team or GP now. Ask when your prescription will be reviewed and who will explain the replacement.
Diabetes UK advises people without an appointment booked by the end of November to contact their healthcare professional. With November now here, there is no advantage in waiting until the last week.
Keep taking your current prescribed insulin as directed until your clinical team tells you how and when to change. Never stop basal insulin or work out a replacement dose from an article online.
If your supply is running low, tell your pharmacist or prescriber promptly. Do not stockpile Levemir. That could worsen shortages and will not avoid the need for a planned switch.
If you're not using Levemir, this specific withdrawal does not mean your insulin is being discontinued. Check the exact name on your prescription if you're unsure.
Will the replacement insulin work the same way?
Not necessarily. Other long-acting insulins are available, including preparations containing insulin glargine and insulin degludec. But they are not identical to Levemir.
Some alternatives last longer, so injection timing or frequency may change. The replacement may use a different pen or cartridge system. Some products also come in different concentrations, which makes clear training particularly important.
Your diabetes team should choose an appropriate option based on individual needs and local availability. They should explain the dose, timing, injection technique and how to monitor glucose during the change.
People using CGM can discuss glucose trends with their team. If you use finger-prick testing, ask how often to check during the transition.
Our earlier Lewcose article on how often to check glucose with a CGM looks at understanding readings without feeling permanently tied to the screen.
What about Northern Ireland and the Republic of Ireland?
This isn't just an issue for England. The Northern Ireland Department of Health published the Levemir safety alert on 5 October 2026, confirming that the withdrawal is relevant locally.
In the Republic of Ireland, the HSE issued a national clinical guideline, effective from 19 March 2026, to help clinicians move people safely to alternative basal insulins. It also issued advice to GPs earlier in the year.
The basic message is the same on both sides of the border: if you use Levemir, make sure your diabetes team has arranged a supervised change.
The precise replacement and appointment process may differ between services.
Five questions worth asking at your appointment
A short list can help, especially if you're helping a child or supporting someone who needs assistance with injections.
- Which insulin am I changing to, and why? Ask what makes it suitable.
- What dose and timing should I use? Get written instructions, including when to take the first new dose.
- Will I need a different pen, needles or cartridges? Ask for a demonstration if anything is unfamiliar.
- How closely should I monitor glucose afterwards? Agree when to review readings and who to contact about unexpected highs or lows.
- What happens if something goes wrong? Check your sick-day and emergency plans and how to obtain out-of-hours advice.
If you use a pump and keep Levemir as emergency backup, ask for that backup plan to be updated as well.
Don't assume the new long-acting insulin can be used in exactly the same way.
Final thoughts
Changing a familiar insulin can feel unsettling, particularly when you have a routine that works. But the purpose of the current safety guidance is to make the change planned, supported and safe, before supplies disappear.
For anyone using Levemir, the most useful step today is straightforward: check whether a switching appointment and written instructions are in place.
If not, contact your diabetes team.
This is general information, not individual dosing advice. Continue following your prescribed treatment. Seek urgent medical help if you cannot obtain essential insulin or develop concerning symptoms.
Paul @ Lewcose
Sources and further reading
1. The Lancet Diabetes & Endocrinology: Original research
Published online 30 October 2026.
Clinical and metabolic subtypes of recent-onset adult Type 1 diabetes: a prospective cohort study
Original German prospective cohort study involving 600 adults, with findings compared against a second dataset of 483 adults. Supports the reported clinical patterns and research limitations.
2. NICE guideline NG17: Type 1 diabetes in adults
Updated 17 August 2022; reviewed 30 January 2026.
UK guidance on diagnosis, autoantibody testing and when C-peptide testing may be appropriate.
3. HSE Ireland: Adult Type 1 Diabetes Mellitus National Clinical Guideline
2026 edition.
Read the HSE clinical guideline
Irish clinical guidance covering diagnosis, investigations and ongoing care.
4. Diabetes UK: Autoantibody testing can help to diagnose diabetes type correctly
Published 26 January 2023.
Read Diabetes UK's research explanation
Explains the problem of diabetes misclassification in adults and the potential value of antibody testing.
5. NHS: Diabetic ketoacidosis
Online guidance accessed 2 November 2026.
Explains DKA warning signs, ketone testing and when emergency medical attention is required.